Diversity of Participants in the 340B Drug Pricing Program for US Hospitals

Sayeh Nikpay; Melinda Buntin; Rena M Conti

doi:10.1001/jamainternmed.2018.2015

Diversity of Participants in the 340B Drug Pricing Program for US Hospitals

JAMA Intern Med. 2018 Aug 1;178(8):1124-1127. doi: 10.1001/jamainternmed.2018.2015.

Authors

Sayeh Nikpay¹, Melinda Buntin¹, Rena M Conti^{2

3}

Affiliations

¹ Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee.
² Section of Pediatric Hematology/Oncology, Department of Pediatrics, University of Chicago, Chicago, Illinois.
³ Department of Public Health Sciences, University of Chicago, Chicago, Illinois.

Abstract

This study examines how uncompensated care, provision of low-profit services, and financial stability differed between nonprofit and public hospitals in the United States that were participating in the 340B drug pricing plan compared with nonparticipating hospitals in 2015.

Publication types

Multicenter Study

MeSH terms

Costs and Cost Analysis / methods*
Drug Costs*
Drug Industry / economics*
Economics, Hospital / statistics & numerical data*
Humans
United States